EULAR 2026 | ABSTRACTS

Submission opens: 1 October 2025 

Submission Deadline: 15 January 2026

Every year EULAR invites abstract submitters from all over the globe to present their work at the European Congress of Rheumatology. In 2026, we will host a Congress with a fully onsite programme and abstract presenters are required to be onsite. 

Our abstract topic chairs and reviewers assess all submitted abstracts and case reports, before inviting the presenting authors to show their work as Oral Abstracts, Poster Tours and Posters onsite in London.

IMPORTANT NOTES

• Abstracts can only be submitted online.
• We discourage splitting data from one study into several abstracts (“salami-slicing”) unless the amount of data cannot be condensed into a single abstract. In the submission forms, authors must indicate whether there are several abstracts related to a single study.
• Submitters will have to choose a Topic, as well as a sub-topic. Sub-topics categorise the abstract as either 'adult rheumatology' or 'paediatric rheumatology'.
• Abstracts should not be submitted if the following applies:
  • the abstract has been published or accepted for publication in a print or online journal before the abstract deadline (15 January 2026). Publication of the abstract in a scientific journal after the submission deadline is not in conflict with presenting it at EULAR congress 2026.
  • the abstract was presented at a scientific meeting more than 12 months prior to EULAR 2026.
    Presentation of an abstract or information thereof at another conference between 1 September 2025 and acceptance notification of the abstract for EULAR 2026 (week of 24 March 2026) is possible. This must be indicated on the abstract submission form.
• Abstracts accepted for the congress are subject to the EULAR Embargo rules. With the submission of an abstract, the authors agree to the embargo rules.
• The inclusion of trade names/brand names is NOT allowed in the abstract, including statistical programmes or other, unless this is peculiar and adds value to their work. The mentioning of agents/molecules must follow the scientific standard for publications.
• For clinical abstract submissions, the presenting author can be any of the listed authors without affiliations to industry. For basic, translational and clinical studies below Phase 2, the presenting author can be any of the listed authors.
• Conflict of interest: It is the intent of EULAR to provide high quality sessions focused on educational content that is free from commercial influence or bias. Thus, the submitting author of an abstract is requested to declare any potential conflicts of interest for all authors during the abstracts' submission.
• Submissions from Russia and Belarus-based institutions or authors will not be accepted. 

REVIEW

• Abstracts are reviewed blindly. The reviewers will judge the abstracts according to the scientific or clinical value, relevance to EULAR, suitability of methods to aims, conclusions confirmed by objective results, objectivity of statements, description of methods used, ethics, originality of work, standard of English and overall impression.
• Abstract acceptance will be in one of four categories:
  • Oral presentation
  • Poster tour presentation
  • Poster view
  • Publication only (no presentation at the Congress, but published in the EULAR Abstract Book).
• Licence agreement: The authors, represented by the presenting author, will have to sign an agreement to grant EULAR the right to use the entire presentation (slides, video and audio recording during the conference) during the congress and subsequently for (paid or unpaid) educational purposes.
• Abstracts not adhering to these guidelines will be rejected. If you do not agree with any of these rules, you should not submit an abstract. The final decision regarding acceptance of an abstract will be taken by the EULAR Scientific Programme Committee. EULAR does not communicate, nor enter into correspondence on the reasons for acceptance or rejection of an abstract.

ACCEPTANCE

• Accepted abstracts will be published in a supplement to the Annals of Rheumatic Diseases (ARD). Information on accepted abstracts (title and presenting author) is available in the online programme. Abstracts will be published in the EULAR Abstract Archive approximately two weeks prior to the congress.
• Case reports will not be added in the ARD and will only be available in the EULAR Abstract Archive.
• The submission of an abstract constitutes a formal commitment by the presenting author to present the abstract (if accepted) orally or as a poster in the session and the time assigned by the EULAR Scientific Programme Committee. We therefore recommend submitters of abstracts to register for the congress at the time of abstract submission.
• If you need to withdraw your abstract, a written statement listing the reasons for this decision must be sent to the abstract help desk at congress.abs@eular.org.

TRAVEL

• Please note that the presenting authors of all accepted abstracts for oral, poster tour and poster view presentations will be required to present physically in London. If, unexpectedly, the presenting author is unable to attend the congress, they would need to assign a co-author to present the abstract onsite.
• If the presenting author needs a letter of invitation for their visa application, they can apply for this via EULAR congress account once they have completed their congress registration. The registration team will provide them with the letter once requested. If the registration is being organised by a third party, they can request a visa letter of invitation on behalf of the presenting author.
• Failure to be onsite at the assigned day and time of presentation will result with abstract being completely removed from the EULAR Abstract Archive and Abstract Book.

FAQS